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Background: All randomised breast cancer screening trials have shown a reduction in breast cancer mortality
in the ‘invited for mammography’ screening arm compared with the ‘control arm’ for women aged 50 years and
older at randomisation (overall 25%). However, individually published point estimates differ and concern has
been raised about methodological quality and outcome measures.
Materials and Methods: Review of the evidence on breast cancer mortality reduction and discussion of the
causes of difference in point estimates in the five Swedish and Canadian trials. A summary of the prerequisites
for methodological quality and its available evidence from the trials is given. Data to support breast cancer mor-
tality as a correct outcome measure are presented.
Results: There is no reason not to use breast cancer mortality as an outcome measure for trials intended to
reduce breast cancer mortality, both from a clinical and a methodological point of view. Everything possible
was performed in these trials in order to determine this outcome measure as accurately as possible. The fact that
a few of the trials showed a relatively large breast cancer mortality reduction and others far lower reduction rates
is irrelevant, if one does not consider the background situation in the region before the trial started, the design of
the trial or quality of screening.
Conclusions: There seems no reason to change or halt the current nation-wide population-based screening
programmes. Nor is there any justifiable reason for negative reports towards women or professionals.
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Introduction
Randomised screening trials are bothersome. It takes ages to come
to an answer, and these need to be large-scale projects to be able to
answer the questions [1]. A sufficient number of persons in the
study arm have to be screened [2], but if randomisation has been
carried out before consent (which is possible, depending on the
local country-specific regulations), attendance for screening may
be (too) low in practice [3]. If randomisation is carried out only
after informed consent, this might affect the attitude of persons
randomised to the control arm and lead to contamination, or it may
lead to selection of enrolled persons in the first place. The long
time-frame of the trials in general has the disadvantage that newer
techniques may have evolved in the meantime, urging investi-
gators to change the screening protocol and therefore possibly
weakening the final results of the trial [4].
Still, such long-term large-scale randomised screening trials are
crucial, and there is no second-best option. Individual randomisa-
tion leads to comparable groups that can be traced for follow-up
and evaluation and the final outcome can be linked directly to
screening and intermediate outcome measures. If there is variation
in screening intensity, this sometimes can be evaluated. There are
enough examples where the lack of randomised trials hamper
present-day evaluations of service screening practice [5–7].
In breast cancer, both clinical and laboratory work support the
theory of breast cancer screening. In the past, women treated by
surgery for smaller tumours had a lower chance of distant meta-
stases after long follow-up [8], and empirical work showed that
treatment before a critical number of blood vessels had formed
might prevent occurrence of metastases [9].
At the request of the Danish Institute for Health Technology
Assessment, Danish researchers analysed and summarised all
available literature on the nine randomised breast cancer screen-
ing trials performed in the past, which was then (partly) approved
by the Cochrane group for publication in their library [10]. The
breast cancer screening trials in question were all initiated during
the period 1963–1982, and were concluded at least 10 years ago.
In a more narrow sense, the review did not include any of the
many breast screening programmes currently ongoing in Europe.
All trials differed in age categories and number of women enrolled,
starting year and place, and the way women were enrolled or
selected. If we confine ourselves to the group of women aged
50 years and older at randomisation, as this is the group that is
invited for screening in every centrally organised European
screening programme, rather than women under the age of 50 years,
all trials had published a reduction in breast cancer mortality in
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the ‘invited for mammography’ screening arm compared with the
‘control’ arm, ranging from 3% to 36% [11, 12].
Causes of difference in point estimates on 
breast cancer mortality in the Swedish and 
Canadian trials
Two trials, one in New York [13] and one in Edinburgh [14],
involved groups in two arms of the trials that were found to be
unfit for comparison, either at the start or on analysis of the results.
In Edinburgh, it ultimately emerged that breast cancer risk was not
equally distributed between the intervention arm and the control
arm of the study, a fact that was later extensively reported on by
the trial’s principal researchers [15]. Therefore, their results could
not easily be utilised in estimating the effect of screening for
breast cancer, nor were they consequently taken into considera-
tion in either the recommendations for The Netherlands or those
for the UK [16, 17]. The imbalance seen during the HIP trial in
New York, on the other hand, came as a surprise. However, an
essential fact is that the outcomes of the HIP trial were disregarded
in the decision-making around many national screening pro-
grammes, as it was universally felt that the point estimate, dating
from the 1960s, could have little relevance in the 1990s in Europe
[18].
The entire discussion as to whether or not a reduction in breast
cancer mortality could be established as a result of screening in
women aged ≥50 years is therefore limited to the five Swedish
studies and the Canadian study, comprising a total of 356000
women. Figure 1 and Table 1 show the relative risk (RR) of women
aged ≥50 years at the start of the trials (Malmö; age ≥55 years)
dying of breast cancer in the intervention arm (‘mammography
screening’) compared with the ‘control’ arm of these trials, sum-
marised in the official Cochrane review [19]. An overall 25%
(11–38%) statistically significant reduction in breast cancer mor-
tality was seen in the intervention arms compared with the control
arms. The overview shows a 12% reduction in breast cancer
mortality in the Malmö and Canada trials (RR = 0.88) and a 31%
reduction in breast cancer mortality (RR = 0.69) in the four other
Swedish trials. All the trials show a breast cancer mortality reduc-
tion for this age group, but only a few were on a large enough scale
individually to reveal a significant reduction.
The fact that a few of the trials showed a relatively large breast
cancer mortality reduction and others far lower reduction rates is
irrelevant, if one does not consider the background situation in
the region before the trial started, the design of the trial or quality
of the screening. The difference between the arms (or before and
after service screening started) is a result of these and other factors
such as attendance figures, detection rates, technical quality and
referral rates. We have already demonstrated that the variation
between the Malmö trial and the Kopparberg/Östergötland trial
could have arisen solely as a consequence of differences in screen-
ing policy (i.e. screening interval, attendance rate, follow-up years).
In fact, based only on trial design characteristics, we would have
expected breast cancer mortality reduction to range from 24% to
32% in the five Swedish trials [20]. The observed reductions, as
published in 1993, for example, represent follow-up years differ-
ing from only 6.2 years for Göteborg to 11.8 years for Malmö
[21], and are likely to influence results [20, 21].
The Canadian trial was the only trial that was uniquely different
in design. The women assigned to the control groups in the Swed-
ish trials were offered no examination, while in the Canadian
trial, the women allotted to the control group annually received an
extensive clinical breast examination, performed by a specially
instructed and trained nurse or physician [22]. This yielded
detection rates in the control arm rivalling those found in some
decentral mammography screening programmes in Europe [23].
In short, one part of the explanation for the relatively small differ-
ence between the two arms in the Canadian trial (a mere 3%) is
explained by the effective screening carried out in the control arm.
This reported point estimate could therefore not be pooled in the
same way with the Malmö trial to compare the effect of mammo-
graphy screening to a no-screen situation, as the effect has been
diluted.
Figure 1. Relative risk (and 95% confidence interval) of dying from breast 
cancer in the mammography intervention arm compared with the ‘control 
arm for women aged ≥50/55 years at the start of the study in the Cochrane 
review of six randomised breast cancer screening trials; 7-year follow-up 
[19]. The Canadian trial included an annual clinical breast examination by a 
nurse or physician in the control arm. Trial names in table 1.
Table 1. Relative risk (RR) of women 
aged ≥50 years at the start of the trials 
dying of breast cancer in the intervention 
arm compared with the control arm
CI, confidence interval.
Trial quality RR with 95% CI
Medium
Malmö 0.80 (0.51–1.24)
Canada 0.97 (0.62–1.52)
Subtotal 0.88 (0.64–1.20)
Low
Kopparberg 0.63 (0.43–0.93)
Östergötland 0.70 (0.47–1.04)
Stockholm 0.59 (0.36–0.98)
Göteborg 0.90 (0.53–1.54) 
Subtotal 0.69 (0.55–0.86)
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Prerequisites for methodological quality of the 
trials
Of course, prerequisites are: (i) a correct randomisation, prefer-
ably at the individual level or with small homogenous blocks; (ii)
post-randomisation exclusions for already existing cancer cases
before randomisation (that are legitimate) being based on the
same type of information in both arms; (iii) adequate follow-up of
deaths in both arms being possible; and (iv) a blinded review of
cause of death. The randomisation methods in the aforementioned
six trials seem to have been justified: they have been based on
computer ranking, printed allocation lists and day of birth as
unit of allocation or an official clerk using the ‘coin-method’ to
randomly allocate geographical areas at the level of village or town,
in the two largest Swedish trials, Kopparberg and Östergötland,
thereby taking socio-economic variations into account [24].
Although it was shown that the women living in the villages ran-
domised to the intervention arm tended on average to be older than
the women living in the villages allotted to the control arm, it was
recently demonstrated that the latter strategy has been successful
and that the heterogeneity between the clusters and within the
strata of the clusters was very small and moreover that this barely
affected the final outcomes [25].
All the Swedish trials were population-based, which means that
in principle, a population list of women was compiled in advance
and randomised. Obviously, it is possible and even likely that this
included women in whom breast cancer had been diagnosed prior
to the randomisation date. These women will have to be excluded
later, for example on the basis of information derived from the
cancer registry. This was the case for a few hundred women in
each Swedish trial. Equal exclusions were reported for Öster-
götland, Malmö and Göteborg, and no age differences were seen
between arms in Stockholm. The Canadian trial was the sole trial
conducted on a volunteer basis, i.e. on women who approached
the centres on their own initiative. Hence, this trial had almost no
exclusions, as women already diagnosed with breast cancer are
unlikely to join, or will not be randomised if they do volunteer.
The Canadian trial is therefore more likely to fulfil this exclusion
criterion, while at the same time saying nothing about a methodo-
logical error or quality criterion. The discussion concerning age
differences between arms constituting the criterion for correct
randomisation [26] has proven to be obsolete and wrong.
Breast cancer mortality as outcome measure
A group of independent clinicians carried out a systematic and
blind assessment of the deaths of all women in the five Swedish
trials in whom breast cancer had been diagnosed (regardless of
how this had been diagnosed and the arm to which they had been
allotted), to determine the cause of death. Blind, in this context,
refers to the fact that the reviewers did not know to which arm the
women belonged, nor in what way the diagnosis had been made.
Table 2 shows the number of deaths attributable to breast cancer
as determined by the Swedish Bureau for Statistics in the arms of
all five Swedish trials, and the figures derived by the independent
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committee. While the absolute figures obviously differ to some
extent, the differences in the reduction of breast cancer mortality
were not significantly affected.
Our own studies have shown that once women develop breast
cancer metastases, sadly, around 95% will go on to die of this
disease [27, 28]. The clinical course of metastatic breast cancer
nearly always ends in a fatal outcome; death from other causes is
rare. The suggestion that breast cancer mortality is an unreliable
outcome measure therefore fails to hold water, both from a clinical
and a methodological point of view.
Evaluation service screening
Various randomised breast cancer screening trials in the past have
demonstrated that a reduction in breast cancer mortality as a result
of screening is certainly feasible for women aged ≥50 years. It
is now time to move on to the evaluations of service screening
programmes. In making the decision to launch a screening pro-
gramme, we estimated that by 1999, around half of the maximum
effect would be visible. It is therefore premature to give any kind
of substantiated opinion based on national mortality figures as to
whether the present breast cancer screening programme is suffi-
ciently or insufficiently effective. The actual impact of the national
screening programme in The Netherlands cannot yet be ascer-
tained. Preparations are currently in progress by the National Evalu-
ation Team for Breast Cancer Screening to gain more insight into
this aspect by means of a detailed mortality review. The popu-
lation screening programme started gradually; it was not until
1993 that over half of the target group was invited for initial
screening, yet by 1997 all the women in the age group between
50 and 69 years had been invited for screening at least once.
Conclusions
Cancer screening has always been a controversial topic, partly
because it concerns the examination of people who are, in princi-
ple, healthy, for whom the health gain must be absolutely undis-
puted. Evidence of this health gain, however, relates to the group
as a whole; at the individual level it is impossible to determine
who will benefit and who will suffer harm. There is a highly deli-
cate balance between favourable and unfavourable effects [29].
This is why extensive analyses of the expected health gain, other
favourable and unfavourable side-effects and the investment
required are carried out prior to introducing large-scale screening
programmes of this kind.
There is no reason not to use breast cancer mortality as an out-
come measure for trials intended to reduce breast cancer mortal-
ity. Everything possible was performed in these trials in order to
determine this outcome measure as correctly as possible.
It is more than likely that the reduction in breast cancer mortal-
ity in the various countries may indeed be attributed to the screen-
ing programmes, although it is still too early for a well-founded,
scientific opinion in this respect. It goes without saying that evalu-
ation of breast cancer mortality during the next 5 years will be
crucial.
There seems no reason to change or to halt the current screening
programmes, for example in The Netherlands. Nor is there any
justifiable reason for negative reports towards women or profes-
sionals.
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